DIAGNOSTIC AND TREATMENT OPTIONS IN AUTISTIC SPECTRUM DIDORDERS – AN OVERVIEW

Sheffali GULATI GULATI

Abstract


Goal: To highlight the recent recommenddations
and future trends in diagnosing and managing
autistic spectrum disorder.
Methodology: Comprehensive search was
done in the electronic database, journals,
reference lists and dissertation related to the
field.
Results and conclusion: Autistic spectrum
disorder is characterized by onset before the
age of 3 years, qualitative impairment in
social and communication skills along with
repetitive behavioural pattern and restricted
interests. Multiple pathways involving
genetic, structural and environmental factors
have been implicated in the etiopathogenesis.
Diagnosis is primarily clinical, based on
caregiver interview and observing the patient.
However, certain biochemical, radiological
and electrophysiological investigations are
indicated in relevant scenarios. The mainstay
of therapy is behavioural intervention with
pharmacotherapy indicated for certain behavioural
issues. Complementary and alternate
treatment, dietary and stem cell therapies are still investigational with some
benefits.Various newer therapeutic options
are currently being investigated, exploring
the molecular and genetic basis of
causation.

Full Text:

PDF

References


The International Statistical Classification of Diseases and Related Health Problems ICD-10, Tokyo. 10th Rev. 2nd ed. U.K: World Health Organisation, 2005.

CDC (Centre for Disease control and Prevention) resource page. Prevalence o Autism Spectrum Disorders-Autism and Developmental Disabilities Monitoring Network (Online). Issued March 30, 2012. Available from URL: www.cdc.gov/mmwr/pdf/ss/ss6103.pdf

Young RL, Rodi ML. Redefining Autistic Spectrum Disorder using DSM V: The implications of the proposed DSM V criteria for Autism Spectrum Disorders. J Autism Dev Disord (published online 22nd September 2013, DOI: 10.1007/s10803-013-1927-3)

Cassanova MF, Mott M. The neuropathology of autism: a selective review. Journal of Special Education and Rehabilitation 2006;7(3-4):21-35.

Silver WG, Rapin I. Neurobiological basis of autism. Pediatr Clin N Am 2012;59(1): 45-61.

Benvenuto A, Moavero R, Alessandrelli R, Manzi B, Curatolo P. Syndromic autism: causes and pathogenetic pathways. World J Pediatr. 2009;5(3):169-176.

NHS (National Institute for Health and Care Excellence) resource page. NICE clinical guideline 128 (Online). Issued September 2011. Available from URL: guidance.nic.org.uk/cg128

NHS (National Institute for Health and Care Excellence) resource page. NICE clinical guideline 170 (Online). Issued August 2013. Available from URL: guidance.nic.org.uk/cg170

Tchaconas A, Adesman A. Autism spectrum disorders: a pediatric overview and update. Curr Opin Pediatr 2013;25(1):130-143.

American Academy of Pediatrics. Autism toolkit, physician fact sheet. 2012.

Sehgal R, Gulati S. Blood heavy metals in children with autism and ADHD: a cross sectional study. Dissertation. All India Institute of Medical Sciences: New Delhi: India, 2012.

Ospina MB, Krebs Seida J, Clark B et al. Behavioural and Developmental Interventions for Autism Spectrum Disorder: A Clinical Systematic Review. PLoS ONE 2008;3(11): e3755.

Bassett K, Green CJ, Kazanjian A. Autism and Lovaas treatment: a systematic review of effectiveness evidence. Annu Meet Int Soc Technol Assess Health Care Int Soc Technol Assess Health Care Meet. 2001;17(20).

Warren Z, McPheeters ML, Sathe N, Foss-Feig JH, Glasser A, Veenstra-Vanderweele J. A systematic review of early intensive intervention for autism spectrum disorders. Pediatrics 2011;127:e1303-11.

Reichow B, Barton EE, Boyd BA, Hume K. Early intensive behavioral intervention (EIBI) for young children with autism spectrum disorders (ASD). Cochrane Database Syst Rev 2012;10:CD009260.

Rogers SJ, Dawson G, Vismara L. An early start for your child with autism. New York: Guilford Press; 2012.

Myers SM, Johnson CP. Management of children with autism spectrum disorders. Pediatrics 2007; 120(5):1162-1175.

Green G, Ricciardi JN, Boyd BA et al. The National Standards Project – addressing the need for evidence-based practice guidelines for autism spectrum disorders. National Autism Center. Massachusettes. National Standards Report 2009.

Oono IP, Honey EJ, McConachie H. Parent-mediated early intervention for young children with autism spectrum disorders (ASD). Cochrane Database Syst Rev 2013;4: CD009774.

Pajareya K, Nopmaneejumruslers K. A pilot randomized controlled trial of DIR/ Floortime parent training intervention for preschool children with autistic spectrum disorders. Autism 2011; 15(5):563-577.

Casenhiser DM, Shanker SG, Stieben J. Learning through interaction in children with autism: preliminary data from a social-communication-based intervention. Autism 2013; 17(2):220-241

Gutstein SE, Sheely RK. Relationship developmental intervention with children, adolescents, and adults. New York, NY: Jessica Kingsley; 2002.

Gutstein SE, Burgess AF, Montfort K. Evaluation of the relationship development intervention program. Autism 2007; 11(5):397-411.

Mesibov GB, Shea V, Schopler E. The TEACCH approach to autism spectrum disorders. New York, NY: Kluwer Academic/Plenum; 2005.

Devlin S, Healy O, Leader G, Hughes BM. Comparison of Behavioral Intervention and Sensory-Integration Therapy in the Treatment of Challenging Behavior. J Autism Dev Disord 2011;41(10):1303-1320.

O’hare A. Autism spectrum disorder: diagnosis and management. Arch Dis Child Educ Pract Ed 2009; 94(6):161-168.

McDougle CJ, Holmes JP, Carlson DC, Pelton GH, Cohen DJ, Price LH. A double-blind, placebo controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry1998; 55(7): 633–641.

Kumar B, Prakash A, Sewal RK, Medhi B, Modi M. Drug therapy in autism: a present and future perspective. Pharmacol Rep 2012; 64(6): 1291-1304.

Di Martino A, Melis G, Cianchetti C, Zuddas A. Methylphenidate for pervasive developmental disorders: safety and efficacy of acute single dose test and ongoing therapy: an open-pilot study. J Child Adolesc Psychopharmacol 2004;14(2):207-218.

Gordon CT, State RC, Nelson JE. A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiatry.1993; 50(6):441-447.

Hollander E, Chaplin W, Soorya L et al. Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology. 2010; 35(4):990-998.

Chez MG, Burton Q, Dowling T, Chang M, Khanna P, Kramer C. Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability. J Child Neurol 2007; 22(5):574-579.

King BH, Wright DM, Handen BL et al. Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. J Am Acad Child Adolesc Psychiatry 2001; 40(6): 658-665.

Nicolson R, Craven-Thuss B, Smith J. A prospective, open-label trial of galantamine in autistic disorder. J Child Adolesc Psychopharmacol 2006;16(5):621-629.

Ming X, Gordon E, Kang N, Wagner GC. Use of clonidine in children with autism spectrum disorders. Brain Dev 2008;30(7):454-460

Elchaar GM, Maisch NM, Augusto LM, Wehring HJ. Efficacy and safety of naltrexone use in pediatric patients with autistic disorder. Ann Pharmacother 2006;40(6):1086-1095.

Wong HH, Smith RG. Patterns of complementary and alternative medical therapy use in children diagnosed with autism spectrum disorders. J Autism Dev Disord 2006;36(7):901-909.

Ravindranath A, Gulati S. Estimation of prevalence of sleep problems in Autistic children in comparison to typically developing children. Dissertation. All India Institute of Medical Sciences: New Delhi:India, 2013.

Wirojanan J, Jacquemont S, Diaz R et al.The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndrome. J Clin Sleep Med 2009;5(2):145-150.

Lofthouse N, Hendren R, Hurt E, Arnold LE, Butter E. A Review of Complementary and Alternative Treatments forAutism Spectrum Disorders. Autism Res Treat 2012; 1-21.

James SJ, Melnyk S, Fuchs G et al. Efficacy of methylcobalamin and folinic acid treatment on glutathione redox status in children with autism. Am J Clin Nutr 2009;89(1):425-430.

Adams JB, Audhya T, McDonough-Means S et al. Effect of a vitamin/mineral supplement on children and adults with autism.BMC Pediatric 2011;11:111.

Adams JB, Baral M, Geis E et al. Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: part B-behavioral results. BMC Clinical Pharmacol 2009; 9:17.

Chez MG, Buchanan CP, Aimonovitch MC et al. Double-blind, placebo-controlled study of L-carnosine supplementation in children with autistic spectrum disorders. J Child Neurol 2002; 17(11):833–837.

Lang R, Koegel LK, Ashbaugh K, Regester A, Ence W, Smith W. Physical exercise and individuals with autism spectrum disorders: a systematic review. Research in Autism Spectrum Disorders.2010;4: 565–576.

Millward C, Ferriter M, Calver S, Connell-Jones G. Gluten- and casein-free diets for autistic spectrum disorder. Cochrane Database Syst Rev.2008; 2:CD003498.

Stafstrom CE, Rho JM. The ketogenic diet as a treatment paradigm for diverse neurological disorders. Front Pharmacol 2012; 3:59.

Siniscalco D, Sapone A, Cirillo A, Giordano C, Maione S, Antonucci N. Autism Spectrum Disorders: Is Mesenchymal Stem Cell Personalized Therapy the Future? J Biomed Biotechnol 2012;2012:480289.

Ehninger D, Siva AJ. Rapamycin for treating Tuberous Sclerosis and Autism Spectrum Disorders. Trends Mol Med 2011;17(2):78-87.

Howlin P, Savage S, Moss P, Tempier A, Rutter M. Cognitive and language skills in adults with autism: a 40 year old follow up. J Child Psychol Psychiatry (published online 15th July 2013, DOI 10.1111/jcpp.12115.)




DOI: http://dx.doi.org/10.2478/jser-2014-0003

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM

Article Metrics Graph

No metrics found.

Refbacks

  • There are currently no refbacks.